ID   PIM2_HUMAN              Reviewed;         311 AA.
AC   Q9P1W9; A8K4G6; Q99739;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   12-OCT-2022, entry version 177.
DE   RecName: Full=Serine/threonine-protein kinase pim-2;
DE            EC=2.7.11.1;
DE   AltName: Full=Pim-2h;
GN   Name=PIM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RX   PubMed=9804974; DOI=10.1016/s0167-4781(98)00185-7;
RA   Baytel D., Shalom S., Madgar I., Weissenberg R., Don J.;
RT   "The human Pim-2 proto-oncogene and its testicular expression.";
RL   Biochim. Biophys. Acta 1442:274-285(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Ishida N., Miura N., Yamauchi M., Kawakita M.;
RT   "Genomic organization of the human UDP-galactose transporter gene.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal
RT   differential cellular gene expression in response to enterovirus 71
RT   infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF CDKN1B.
RX   PubMed=18593906; DOI=10.1158/0008-5472.can-08-0634;
RA   Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.;
RT   "Pim kinases promote cell cycle progression by phosphorylating and down-
RT   regulating p27Kip1 at the transcriptional and posttranscriptional levels.";
RL   Cancer Res. 68:5076-5085(2008).
RN   [8]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=18675992; DOI=10.1016/j.jss.2008.03.033;
RA   Gong J., Wang J., Ren K., Liu C., Li B., Shi Y.;
RT   "Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction
RT   through mediating survival and preventing apoptosis of liver cell.";
RL   J. Surg. Res. 153:17-22(2009).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CDKN1A.
RX   PubMed=20307683; DOI=10.1016/j.biocel.2010.03.012;
RA   Wang Z., Zhang Y., Gu J.J., Davitt C., Reeves R., Magnuson N.S.;
RT   "Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and
RT   inhibits cell proliferation in HCT116 cells.";
RL   Int. J. Biochem. Cell Biol. 42:1030-1038(2010).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH
RP   RUTHENIUM-PYRIDOCARBAZOLE-1.
RX   PubMed=19841674; DOI=10.1371/journal.pone.0007112;
RA   Bullock A.N., Russo S., Amos A., Pagano N., Bregman H., Debreczeni J.E.,
RA   Lee W.H., von Delft F., Meggers E., Knapp S.;
RT   "Crystal structure of the PIM2 kinase in complex with an organoruthenium
RT   inhibitor.";
RL   PLoS ONE 4:E7112-E7112(2009).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-138 AND VAL-280.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Proto-oncogene with serine/threonine kinase activity involved
CC       in cell survival and cell proliferation. Exerts its oncogenic activity
CC       through: the regulation of MYC transcriptional activity, the regulation
CC       of cell cycle progression, the regulation of cap-dependent protein
CC       translation and through survival signaling by phosphorylation of a pro-
CC       apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of
CC       MYC protein stability and thereby an increase transcriptional activity.
CC       The stabilization of MYC exerted by PIM2 might explain partly the
CC       strong synergism between these 2 oncogenes in tumorigenesis. Regulates
CC       cap-dependent protein translation in a mammalian target of rapamycin
CC       complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt
CC       pathway. Mediates survival signaling through phosphorylation of BAD,
CC       which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1.
CC       Promotes cell survival in response to a variety of proliferative
CC       signals via positive regulation of the I-kappa-B kinase/NF-kappa-B
CC       cascade; this process requires phosphorylation of MAP3K8/COT. Promotes
CC       growth factor-independent proliferation by phosphorylation of cell
CC       cycle factors such as CDKN1A and CDKN1B. Involved in the positive
CC       regulation of chondrocyte survival and autophagy in the epiphyseal
CC       growth plate. {ECO:0000269|PubMed:18593906,
CC       ECO:0000269|PubMed:18675992, ECO:0000269|PubMed:20307683}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Interacts with MYC. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9P1W9; P54253: ATXN1; NbExp=4; IntAct=EBI-720425, EBI-930964;
CC       Q9P1W9; O75541: ZNF821; NbExp=3; IntAct=EBI-720425, EBI-740865;
CC   -!- TISSUE SPECIFICITY: Highly expressed in hematopoietic tissues, in
CC       leukemic and lymphoma cell lines, testis, small intestine, colon and
CC       colorectal adenocarcinoma cells. Weakly expressed in normal liver, but
CC       highly expressed in hepatocellular carcinoma tissues.
CC       {ECO:0000269|PubMed:18675992}.
CC   -!- INDUCTION: Down-regulated in response to enterovirus 71 (EV71)
CC       infection. {ECO:0000269|PubMed:16548883}.
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. PIM subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC78506.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U77735; AAC78506.1; ALT_FRAME; mRNA.
DR   EMBL; AK290931; BAF83620.1; -; mRNA.
DR   EMBL; AB042425; BAA95613.1; -; Genomic_DNA.
DR   EMBL; AF207550; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC018111; AAH18111.1; -; mRNA.
DR   CCDS; CCDS14312.1; -.
DR   RefSeq; NP_006866.2; NM_006875.3.
DR   PDB; 2IWI; X-ray; 2.80 A; A/B=1-311.
DR   PDB; 4X7Q; X-ray; 2.33 A; A/B=1-311.
DR   PDBsum; 2IWI; -.
DR   PDBsum; 4X7Q; -.
DR   AlphaFoldDB; Q9P1W9; -.
DR   SMR; Q9P1W9; -.
DR   BioGRID; 116228; 28.
DR   IntAct; Q9P1W9; 25.
DR   MINT; Q9P1W9; -.
DR   STRING; 9606.ENSP00000365692; -.
DR   BindingDB; Q9P1W9; -.
DR   ChEMBL; CHEMBL4523; -.
DR   DrugCentral; Q9P1W9; -.
DR   GuidetoPHARMACOLOGY; 2159; -.
DR   iPTMnet; Q9P1W9; -.
DR   PhosphoSitePlus; Q9P1W9; -.
DR   BioMuta; PIM2; -.
DR   DMDM; 20139243; -.
DR   EPD; Q9P1W9; -.
DR   MassIVE; Q9P1W9; -.
DR   MaxQB; Q9P1W9; -.
DR   PaxDb; Q9P1W9; -.
DR   PeptideAtlas; Q9P1W9; -.
DR   PRIDE; Q9P1W9; -.
DR   ProteomicsDB; 83676; -.
DR   Antibodypedia; 415; 483 antibodies from 40 providers.
DR   DNASU; 11040; -.
DR   Ensembl; ENST00000376509.4; ENSP00000365692.4; ENSG00000102096.9.
DR   GeneID; 11040; -.
DR   KEGG; hsa:11040; -.
DR   MANE-Select; ENST00000376509.4; ENSP00000365692.4; NM_006875.4; NP_006866.2.
DR   UCSC; uc004dls.4; human.
DR   CTD; 11040; -.
DR   DisGeNET; 11040; -.
DR   GeneCards; PIM2; -.
DR   HGNC; HGNC:8987; PIM2.
DR   HPA; ENSG00000102096; Tissue enhanced (bone marrow, intestine, lymphoid tissue).
DR   MIM; 300295; gene.
DR   neXtProt; NX_Q9P1W9; -.
DR   OpenTargets; ENSG00000102096; -.
DR   PharmGKB; PA33319; -.
DR   VEuPathDB; HostDB:ENSG00000102096; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   GeneTree; ENSGT00940000161689; -.
DR   InParanoid; Q9P1W9; -.
DR   OMA; QWARLPG; -.
DR   OrthoDB; 930292at2759; -.
DR   PhylomeDB; Q9P1W9; -.
DR   TreeFam; TF320810; -.
DR   PathwayCommons; Q9P1W9; -.
DR   SignaLink; Q9P1W9; -.
DR   SIGNOR; Q9P1W9; -.
DR   BioGRID-ORCS; 11040; 23 hits in 738 CRISPR screens.
DR   ChiTaRS; PIM2; human.
DR   EvolutionaryTrace; Q9P1W9; -.
DR   GeneWiki; PIM2_(gene); -.
DR   GenomeRNAi; 11040; -.
DR   Pharos; Q9P1W9; Tchem.
DR   PRO; PR:Q9P1W9; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9P1W9; protein.
DR   Bgee; ENSG00000102096; Expressed in granulocyte and 119 other tissues.
DR   ExpressionAtlas; Q9P1W9; baseline and differential.
DR   Genevisible; Q9P1W9; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017348; PIM1/2/3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037993; STPK_Pim-1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cell cycle; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..311
FT                   /note="Serine/threonine-protein kinase pim-2"
FT                   /id="PRO_0000086532"
FT   DOMAIN          32..286
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..20
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        163
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         38..46
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         61
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   VARIANT         138
FT                   /note="G -> D (in dbSNP:rs35044770)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041008"
FT   VARIANT         280
FT                   /note="I -> V (in dbSNP:rs35208542)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041009"
FT   CONFLICT        66
FT                   /note="N -> Y (in Ref. 2; BAF83620)"
FT                   /evidence="ECO:0000305"
FT   HELIX           28..31
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          32..39
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          45..51
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   TURN            52..54
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          57..62
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   TURN            66..68
FT                   /evidence="ECO:0007829|PDB:2IWI"
FT   HELIX           82..91
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          97..99
FT                   /evidence="ECO:0007829|PDB:2IWI"
FT   STRAND          102..106
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          113..117
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          120..124
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           125..132
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           137..156
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           166..168
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          169..172
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   TURN            173..176
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   STRAND          177..180
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           201..203
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           206..211
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           216..233
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           241..246
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           257..266
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           271..273
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           277..281
FT                   /evidence="ECO:0007829|PDB:4X7Q"
FT   HELIX           284..286
FT                   /evidence="ECO:0007829|PDB:4X7Q"
SQ   SEQUENCE   311 AA;  34190 MW;  160E56C368C67A69 CRC64;
     MLTKPLQGPP APPGTPTPPP GGKDREAFEA EYRLGPLLGK GGFGTVFAGH RLTDRLQVAI
     KVIPRNRVLG WSPLSDSVTC PLEVALLWKV GAGGGHPGVI RLLDWFETQE GFMLVLERPL
     PAQDLFDYIT EKGPLGEGPS RCFFGQVVAA IQHCHSRGVV HRDIKDENIL IDLRRGCAKL
     IDFGSGALLH DEPYTDFDGT RVYSPPEWIS RHQYHALPAT VWSLGILLYD MVCGDIPFER
     DQEILEAELH FPAHVSPDCC ALIRRCLAPK PSSRPSLEEI LLDPWMQTPA EDVPLNPSKG
     GPAPLAWSLL P
//
